Silvina Grasso
Overview
Explore the profile of Silvina Grasso including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
167
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Grasso S, Pereira G, Palmeira-Dos-Santos C, Calgarotto A, Martinez-Lacaci I, Ferragut J, et al.
Eur J Med Chem
. 2016 Jul;
122:611-618.
PMID: 27448918
Objective: As Selumetinib is a MEK1/2 inhibitor that has gained interest as an anti-tumor agent, the present study was designed to investigate autophagy involvement on Selumetinib-induced apoptosis in colorectal cancer...
2.
Grasso S, Martinez-Lacaci I, Barbera V, Castillejo A, Soto J, Gallego-Plazas J, et al.
BMC Cancer
. 2015 Apr;
15:240.
PMID: 25885658
Background: Colorectal carcinoma is a common cause of cancer. Adjuvant treatments include: 5-fluorouracil administered together with folinic acid, or more recently, oral fluoropyrimidines such as capecitabine, in combination with oxaliplatin...
3.
Mayor-Lopez L, Tristante E, Carballo-Santana M, Carrasco-Garcia E, Grasso S, Garcia-Morales P, et al.
Transl Oncol
. 2014 Nov;
7(5):590-604.
PMID: 25389454
Nad(p)h: quinone oxidoreductase 1 (NQO1) enzyme and activity. However, colorectal LoVo cells still responded to both drugs in spite of having undetectable levels and activity of NQO1. Pharmacological and biologic...
4.
Grasso S, Tristante E, Saceda M, Carbonell P, Mayor-Lopez L, Carballo-Santana M, et al.
Neoplasia
. 2014 Nov;
16(10):845-60.
PMID: 25379021
Selumetinib (AZD6244, ARRY-142886) is a MEK1/2 inhibitor that has gained interest as an anti-tumour agent. We have determined the degree of sensitivity/resistance to Selumetinib in a panel of colorectal cancer...
5.
Carrasco-Garcia E, Saceda M, Grasso S, Rocamora-Reverte L, Conde M, Gomez-Martinez A, et al.
Exp Cell Res
. 2011 Mar;
317(10):1476-89.
PMID: 21439954
Signaling through the epidermal growth factor receptor (EGFR) is relevant in glioblastoma. We have determined the effects of the EGFR inhibitor AG1478 in glioblastoma cell lines and found that U87...
6.
Grasso S, Hernandez J, Chifflet S
Am J Physiol Cell Physiol
. 2007 Aug;
293(4):C1327-37.
PMID: 17687005
It has classically been accepted that the healing of narrow wounds in epithelia occurs by the formation of a contractile actin cable, while wide wounds are resurfaced by lamellipodia-dependent migration...
7.
Chifflet S, Hernandez J, Grasso S
Am J Physiol Cell Physiol
. 2005 May;
288(6):C1420-30.
PMID: 15897322
Linear narrow wounds produced on cultured bovine corneal endothelial monolayers heal by actin cable formation at the wound border and lamellar crawling of cells into the injured area. We report...
8.
Chifflet S, Hernandez J, Grasso S, Cirillo A
Exp Cell Res
. 2002 Dec;
282(1):1-13.
PMID: 12490189
Modifications in the cell membrane potential have been suggested to affect signaling mechanisms participating in diverse cellular processes, many of which involve structural cellular alterations. In order to contribute some...